We have advised Blau Farmacêutica, a listed leader in the US and South American pharmaceutical industry. We guided their investment in Prothya (www.prothya.com), one of the 10 biggest companies in the plasma fractionation sector.
Our team consisted of Gaby Heere, Jan-Berend Möller and Pien Obbes.
Blau Farmacêutica, in line with the internationalization strategy of its operations, concludes the closing of the convertible loan agreement with Prothya - one of the 10 largest companies in the plasma fractionation sector in the world and headquartered in the Netherlands. This transaction reinforces Blau's Biotechnology DNA and its spirit of vanguard and innovation. With the investment of € 50 million, Blau became the first Brazilian company to be part of this select worldwide group of fractionating companies and producers of medicines derived from human plasma. Blau may also, in due course, convert the loan into 20% of Prothya's share capital.
Our team – together with our Belgian colleagues at Monard Law – guided Blau through the entire legal process of this investment. Due to Kennedy van der Laan's extensive knowledge, experience and large network within the transaction practice and the Life Science & Healthcare sector, the cooperation proved to be successful as a multidisciplinary crossborder team for transactions in this sector.
Blau is a leading pharmaceutical industry in the institutional segment and a pioneer in biotechnology, with an owned brands portfolio of highly complex drugs focused on relevant segments in the industry, such as immunology, hematology, oncology, nephrology, infectiology, operating in different therapeutic classes. Blau has a continental footprint, present in 7 countries in Latin American – Brazil, Argentina, Colombia, Chile, Ecuador, Peru, Uruguay – and the United States, and has a modern pharmaceutical industrial complex in Brazil, composed of five industrial facilities, with state-of-the-art technology, dedicated to the production of biological and synthetic products.
We congratulate Blau with their investment and look forward to seeing more of their innovations in the future. Please find the press statement of Blau via this link.
